Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02324647

Acronym

SERENDIPITY

Enrollment

807

Registered

2014-12-24

Start date

2015-01-31

Completion date

2023-06-30

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Incidentaloma, Adrenocortical Carcinoma

Keywords

Urinary steroid profiling, Adrenal incidentaloma, Adrenocortical carcinoma, cost-effectiveness

Brief summary

Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical carcinoma (ACC), respectively. The overall aim of this study is to improve the cost-effectiveness of the diagnostic strategy for AI. Cost-effectiveness of urine steroid profiling (USP) will be compared to the standard diagnostic strategy of repeated CT-imaging.

Detailed description

Rationale: Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical carcinoma (ACC),respectively. With respect to the diagnosis of ACC, the health benefits of this strategy are controversial for the following reasons: a. critical appraisal of literature has revealed a much lower ACC frequency of 1.9% than previously presumed; b. CT sensitivity and specificity are suboptimal; c. risk of unnecessary adrenalectomies; d. exposure to ionising radiation; e. risk of CT contrast reactions (nephropathy, allergic reaction); f. health care related and economical costs. The hypothesis to be tested is that incorporation of a single baseline urinary steroid profiling (USP) into the management algorithm of AI is more cost-effective than a strategy solely based on repeat CT-scanning. Objective: SERENDIPITY aims to improve the cost-effectiveness of the diagnostic strategy for AI by the application of a single baseline USP. In addition, we aim to examine the psychological impact for patients with AI being currently subjected to repeated laboratory tests and CT-scanning during several years. Study design: This is a prospective observational multicenter study. Study population: Patients are eligible if they meet the following inclusion criteria: adrenal mass \> 1 cm in diameter incidentally discovered during CT or MRI-scanning, performed for reasons other than an evaluation for adrenal disease and age 18 years or older. The exclusion criteria are: extra-adrenal malignancy (i.e. active or past medical history of malignancy, except for basal cell carcinoma), radiologic diagnosis of simple cyst or bilateral adrenal masses, allergy to radiocontrast, renal insufficiency (i.e. eGFR \< 30 ml/min/1.73m2), pregnancy or inability to understand written Dutch.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* discrete adrenal mass \> 1 cm in diameter incidentally discovered during CT/MRI-scanning, performed for reasons other than an evaluation for adrenal disease * detection CT/MRI-scan performed ≤ 4 months ago * age 18 years or older.

Exclusion criteria

* extra-adrenal malignancy (i.e. active or past medical history of malignancy, except for basal cell carcinoma) * radiologic diagnosis of simple cyst or bilateral adrenal masses * allergy to radiocontrast * renal insufficiency (i.e. eGFR \< 30 ml/min/1.73m2) * pregnancy * adrenal incidentaloma visible on previous (i.e. \> 4 months ago) CT/MRI-scan * inability to understand written Dutch.

Design outcomes

Primary

Measure	Time frame	Description
Cost-effectiveness	2 years	difference in cost-effectiveness of the current management strategy based on repeat CT-scanning to detect ACC among patients with an AI compared with a strategy using a single baseline USP

Secondary

Measure	Time frame
determination of the percentage of AI that meets the criteria of a malignant CT- phenotype at baseline or during follow-up	2 years
distribution of pathologic diagnosis in surgically removed adrenal glands	2 years
QoL in patients with an AI at baseline and during follow-up	2 years
frequency of ACC among patients with AI at baseline or during follow-up	2 years
conversion rate from non-functioning AI towards a hypersecreting AI during follow-up	2 years
costs of diagnostic procedures and surgical interventions	2 years
frequency distribution between hormonal hypersecreting and non-functional AI	2 years

Countries

Netherlands

Outcome results